<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03406104</url>
  </required_header>
  <id_info>
    <org_study_id>GS-LHON-CLIN-06</org_study_id>
    <secondary_id>2017-002153-11</secondary_id>
    <nct_id>NCT03406104</nct_id>
  </id_info>
  <brief_title>RESCUE and REVERSE Long-term Follow-up</brief_title>
  <acronym>RESCUE/REVERSE</acronym>
  <official_title>Long-term Follow-up of ND4 LHON Subjects Treated With GS010 Ocular Gene Therapy in the RESCUE or REVERSE Phase III Clinical Trials</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GenSight Biologics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GenSight Biologics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical trial is to assess the long-term safety and efficacy of GS010, a
      gene therapy, and assess the quality of life in subjects with LHON due to the G11778A ND4
      mitochondrial mutation and who were treated in the Rescue or Reverse studies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 9, 2018</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events (AEs) or serious adverse events (SAEs) (ocular or systemic)</measure>
    <time_frame>Up to 5-Year post-treatment</time_frame>
    <description>AEs or SAEs (ocular or systemic) related to IMP or administration procedure, as judged by the Investigator, reported during the long-term follow-up visits (2, 2.5, 3, 4, and 5 years) from the period of 96 weeks up to 5 years post-treatment and summarized descriptively by type, frequency (number, percentage), severity, causal relationship, and seriousness</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best-Corrected Visual Acuity (BCVA) reported with LogMAR</measure>
    <time_frame>Up to 5-Year post-treatment</time_frame>
    <description>Change in best BCVA reported with LogMAR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HumphreyTM visual field (HVF) 30-2 parameters</measure>
    <time_frame>Up to 5-Year post-treatment</time_frame>
    <description>Change of parameters measured with HVF 30-2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spectral domain optical coherence tomography (SD-OCT) parameters</measure>
    <time_frame>Up to 5-Year post-treatment</time_frame>
    <description>Change of parameters measured with SD-OCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder Analysis</measure>
    <time_frame>Up to 5-Year post-treatment</time_frame>
    <description>Response status of eyes treated with GS010 IVT injection compared to eyes treated with sham IVT injection (An improvement of at least 15 ETDRS letters/Eyes that lose less than the 15 ETDRS letters)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time course of the response</measure>
    <time_frame>Up to 5-Year post-treatment</time_frame>
    <description>Time course of the response in eyes treated with GS010 IVT injection compared to eyes treated with sham IVT injection, for the BCVA reported with LogMAR, for parameters measured with HVF 30-2 and SD-OCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual improvement</measure>
    <time_frame>Up to 5-Year post-treatment</time_frame>
    <description>Visual improvement as measured by LogMAR by analysis of covariance (ANCOVA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of ganglion cell layer (GCL) thickness/volume and topographical map and other parameters measured by SD-OCT</measure>
    <time_frame>Up to 5-Year post-treatment</time_frame>
    <description>Change of GCL thickness/volume and topographical map and other parameters measured by SD-OCT using a mixed model of ANCOVA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life: Visual Functioning Questionnaire 25 (VFQ-25)</measure>
    <time_frame>Up to 5-Year post-treatment</time_frame>
    <description>QOL as measured with VFQ-25 subject-rated instrument</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life: 36-Item Short Form Health Survey, version 2 (SF-36-v2)</measure>
    <time_frame>Up to 5-Year post-treatment</time_frame>
    <description>QOL as measured with SF-36v2 subject-rated instrument</description>
  </secondary_outcome>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Leber Hereditary Optic Neuropathy (Optic, Atrophy, Hereditary, Leber)</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>GS010</intervention_name>
    <description>Different procedures will be performed in order to assess the safety and efficacy of GS010 up to 5 years post-treatment</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham Intravitreal Injection</intervention_name>
    <description>Different procedures will be performed in order to assess the safety and efficacy of GS010 up to 5 years post-treatment</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Hematology, Serum chemistry and liver function tests
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will include subjects who were treated with GS010 in either of the 2
        Phase III trialsâ€”RESCUE and REVERSE
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria Subjects must meet all the following criteria at Inclusion period to be
        eligible for inclusion.

          -  Subject was treated with GS010 IVT injection in either of the RESCUE or REVERSE Phase
             III clinical studies

          -  Subject of legal consent age has provided informed consent; subjects that are not of
             legal consent age have undergone their country-approved clinical trial enrollment
             consent process

        Non-Inclusion Criteria Subjects meeting any of the following criteria at Inclusion period
        will be excluded from eligibility.

          -  Subject is unwilling or unable to comply with the protocol requirements

          -  Subject has any medical or psychological condition that, in the opinion of the
             Investigator, may compromise his or her safe participation in the study

          -  Subject is taking or intending to take idebenone during the long-term follow-up study
             period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Barrett Katz, MD</last_name>
    <phone>+1-646-831-3799</phone>
    <email>bkatz@gensight-biologics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Serge Fitoussi, MD</last_name>
    <phone>+33 (0)6 65 75 78 41</phone>
    <email>sfitoussi@gensight-biologics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Doheny Eye Center UCLA</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosio Mendoza</last_name>
      <email>r.mendoza@jsei.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Alfredo Sadun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lindy Dubois</last_name>
      <email>ldubois@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Nancy Newman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wills Eye Institute</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Massini</last_name>
      <email>mmassini@willseye.org</email>
    </contact>
    <investigator>
      <last_name>Mark Moster, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHNO Les Quinze Vingts</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lise Plaine</last_name>
      <email>lplaine@15-20.fr</email>
    </contact>
    <investigator>
      <last_name>Catherine Vignal-Clermont, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LMU Klinikum der UniversitÃ¤t MÃ¼nchen / Friedrich-Baur-Institut</name>
      <address>
        <city>Munich</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claudia Catarino, MD</last_name>
      <email>Claudia.catarino@med.uni-muenchen.de</email>
    </contact>
    <investigator>
      <last_name>Thomas Klopstock, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Bellaria</name>
      <address>
        <city>Bologna</city>
        <zip>40139</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chiara La Morgia, MD</last_name>
      <email>chiaralamorgia@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Valerio Carelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moorfields Eye Hospital</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>EC1V 2PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lauren Leitch-Devlin</last_name>
      <email>lauren.leitch-devlin@moorfields.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Patrick Yu Wai Man, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.gensight-biologics.com/index.php?page=lhon-leber-hereditary-optic-neuropathy</url>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2018</study_first_submitted>
  <study_first_submitted_qc>January 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2018</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heredity Optic Atrophy</keyword>
  <keyword>Leber Hereditary Optic Atrophy</keyword>
  <keyword>Leber Hereditary Optic Neuropathy</keyword>
  <keyword>LHON</keyword>
  <keyword>Eye Diseases</keyword>
  <keyword>Hereditary Eye Diseases</keyword>
  <keyword>Inborn Genetic Disease</keyword>
  <keyword>Gene Therapy</keyword>
  <keyword>Intravitreal Injections</keyword>
  <keyword>Mitochondrial Disease</keyword>
  <keyword>AAV2 Vectors</keyword>
  <keyword>Nervous System Diseases</keyword>
  <keyword>Neurodegenerative Disease</keyword>
  <keyword>Heredodegenerative Disorders of the Nervous System</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Optic Nerve Diseases</mesh_term>
    <mesh_term>Optic Atrophy, Hereditary, Leber</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

